

NOTIFICATION LETTER 通知信函

29 September 2026

Dear non-registered holders of securities of the Company^(Note 1),

SinoMab BioScience Limited (the “Company”)
– Notice of Publication of Interim Report 2026 (the “Current Corporate Communications”)

The Current Corporate Communications of the Company have been published in English and Chinese languages and are available on the HKExnews website of The Stock Exchange of Hong Kong Limited (“HKEx”) at www.hkexnews.hk (the “HKExnews Website”) and the Company’s website at www.sinomab.com (the “Company Website”). If you have any difficulty in receiving or gaining access to the Current Corporate Communications posted on the aforesaid websites for any reason, please send your request (specifying your name, address and request) by email to message@sinomab.com or by notice in writing to the Company’s share registrar (the “Share Registrar”), Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wan Chai, Hong Kong. The Company will promptly upon receipt of your request send the Current Corporate Communications to you in printed form free of charge.

Arrangement of Electronic Dissemination of Corporate Communications

Pursuant to Rule 2.07A of the Rules Governing The Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”) in respect of the expansion of paperless listing regime and electronic dissemination of corporate communications that came into effect on 31 December 2023, the Company is writing to inform you that the Company has adopted electronic dissemination of corporate communications (the “Corporate Communications”), which term under the Listing Rules means any document issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to (a) the directors’ report, its annual accounts together with a copy of the auditors’ report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; and (f) a proxy form.

Please note that both the English and Chinese versions of all future Corporate Communication(s) will be available electronically on the Company Website at www.sinomab.com and on the HKExnews Website at www.hkexnews.hk in place of printed copies.

As a non-registered holder, if you wish to receive Corporate Communications from the Company by email pursuant to the Listing Rules, you should liaise with your bank(s), broker(s), custodian(s), nominee(s) or HKSCC Nominees Limited through which your Shares are held (collectively, the “Intermediaries”) and provide your email address to your Intermediaries.

If the Company does not receive your functional email address from the Intermediaries, until such time that the functional email address is provided to the Intermediaries, you will (i) be unable to receive any notifications regarding the publication of Corporate Communications; and (ii) need to proactively check the Company Website and the HKExnews Website to keep up with the publication of Corporate Communications.

If you want to receive the future Corporate Communications^(Note 2) and/or Actionable Corporate Communications in printed form, please complete and return the reply form on the reverse side to the Share Registrar or send an email with a scanned copy of the duly completed reply form to message@sinomab.com.

Should you have any queries relating to this letter, please contact the Company at (852) 3426 9833 during business hours from 8:30 a.m. to 5:30 p.m. (Hong Kong time), Mondays to Fridays, excluding Hong Kong public holidays, or by sending an email to message@sinomab.com.

Yours faithfully,
By order of the Board
SinoMab BioScience Limited
Dr. Shui On LEUNG
Executive Director, Chairman and Chief Executive Officer

Note 1: This letter is addressed to non-registered holders (“non-registered holder” means such person or company whose shares are held in The Central Clearing and Settlement System (CCASS), either directly as a beneficial shareholder or through a broker or custodian, and who has notified the Company from time to time through Hong Kong Securities Clearing Company Limited of his/her/its wishes to receive Corporate Communications). If you have sold or transferred your shares in the Company, please disregard this letter and the Reply Form on the reverse side.

Note 2: Corporate Communications refer to any documents issued or to be issued by the Company for the information or action of holders of any of its securities, including, but not limited to, (a) the directors’ report, its annual accounts together with a copy of the auditors’ report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; and (f) a proxy form. Pursuant to Rule 1.01 of the Listing Rules, Actionable Corporate Communications are any corporate communications that seek instructions from issuer’s securities holders on how they wish to exercise their rights or make an election as the issuer’s securities holder.

各位本公司證券的非登記持有人^(附註 1)：

中國抗體製藥有限公司（「本公司」）
– 中期報告 2026（「本次公司通訊文件」）之發佈通知

本公司的本次公司通訊文件備有中、英文版本，並已上載於香港聯合交易所有限公司（「香港交易所」）披露易之網站（www.hkexnews.hk）（「披露易網站」）及本公司網站（www.sinomab.com）（「公司網站」），歡迎瀏覽。閣下若因任何理由以致在收取或接收載於前述網址上的本次公司通訊文件出現困難，閣下可將要求（註明閣下的姓名、地址及要求）以電郵方式發送到本公司之電郵地址 message@sinomab.com 或以書面方式郵寄致本公司的股份過戶登記處（「股份過戶處」）香港中央證券登記有限公司，地址為香港灣仔皇后大道東 183 號合和中心 17M 樓。本公司將於接到閣下通知後，盡快向閣下免費發送有關本次公司通訊文件的印刷本。

以電子方式發布公司通訊之安排

根據於 2023 年 12 月 31 日起生效的香港聯合交易所有限公司證券上市規則（「上市規則」）第 2.07A 條有關擴大無紙化上市機制及以電子方式發布公司通訊之規定，本公司謹此通知閣下其就採用以電子方式發布公司通訊（「公司通訊」）作出安排，該詞語根據上市規則是指本公司發出或將予發出以供其任何證券持有人參照或採取行動的任何文件，其中包括但不限於 (a) 董事會報告、年度帳目連同核數師報告以及（如適用）財務摘要報告；(b) 中期報告及（如適用）其中期摘要報告；(c) 會議通告；(d) 上市文件；(e) 通函；及 (f) 代表委任表格。

請注意，日後所有公司通訊的英文版本及中文版本將可在公司網站 www.sinomab.com 及披露易網站 www.hkexnews.hk 上提供電子版，以代替印刷本。

作為非登記持有人，如閣下有意根據上市規則自本公司收取公司通訊，閣下應聯絡代閣下持有股份的銀行、經紀、託管商、代理人或香港中央結算（代理人）有限公司（統稱「中介公司」），並向閣下的中介公司提供閣下的電子郵件地址。

如果本公司沒有從中介公司收到閣下的有效電子郵件地址，直至中介公司收到閣下有效的電子郵件地址前，閣下或 (i) 無法收到任何有關發布公司通訊的通知；及 (ii) 需要主動查看公司網站和披露易網站以留意公司通訊的發佈。

若閣下希望收取未來的公司通訊^(附註 2)及/或可供採取行動的公司通訊之印刷版，請填妥本函背頁之回條並交回公司的股份過戶處，或把已填妥之回條的掃描副本以電郵發送至 message@sinomab.com。

如閣下對本函有任何疑問，請於辦公時間星期一至星期五（香港公眾假期除外）上午八時三十分至下午五時三十分（香港時間）致電本公司(852) 3426 9833 查詢，或電郵至 message@sinomab.com。

承董事會命
中國抗體製藥有限公司
執行董事、主席兼首席執行官
梁瑞安博士
謹啟

二零二六年九月二十九日

附註 1：此函件乃向本公司之非登記持有人發出（「非登記持有人」指股份存放於中央結算及交收系統的人士或公司，及不時透過香港中央結算有限公司通知本公司希望收到公司通訊的人士或公司（彼等直接實益持有股份，或透過經紀或保管人持有該等股份）。如果閣下已經出售或轉讓所持有之本公司股份，則無需理會本函件及背面的回條。

附註 2：公司通訊乃指本公司發出或將予發出以供其任何證券持有人參照或採取行動的任何文件，其中包括但不限於：(a) 董事會報告、年度帳目連同核數師報告的副本以及（如適用）財務摘要報告；(b) 中期報告及（如適用）其中期摘要報告；(c) 會議通告；(d) 上市文件；(e) 通函；及(f) 代表委任表格。根據上市規則第 1.01 條，「可供採取行動的公司通訊」指任何涉及要求發行人的證券持有人指示其擬如何行使其有關證券持有人的權利或作出選擇的公司通訊。

**REPLY FORM 回條**

To: SinoMab BioScience Limited (the “Company”)
(Stock Code: 3681)
c/o Computershare Hong Kong Investor Services Limited
(The “Share Registrar”)
17M Floor, Hopewell Centre
183 Queen’s Road East, Wanchai, Hong Kong

致：中國抗體製藥有限公司
(股份代號：3681)
經香港中央證券登記有限公司
(「股份過戶處」)
香港灣仔皇后大道東 183 號
合和中心 17M 樓

REMINDER 提示

As a non-registered holder, if you wish to receive Corporate Communications* pursuant to the Listing Rules, you should liaise with your bank(s), broker(s), custodian(s), nominee(s) or HKSCC Nominees Limited through which your shares are held (collectively, the “Intermediaries”) and provide your email address to your Intermediaries if you wish to receive any notifications regarding the publication of Corporate Communications.

作為非登記持有人，如有意根據《上市規則》收取公司通訊*，閣下應聯絡閣下持有股份的銀行、經紀、託管商、代理人或香港中央結算（代理人）有限公司（統稱「中介公司」），且如希望收到任何有關發佈公司通訊的通知，亦應向閣下的中介公司提供閣下的電子郵件地址。

Request for Corporate Communications* in printed form / 要求收取公司通訊*印刷版

(Please mark “✓” in the below box if applicable) (如適用，請在以下方格內劃上「✓」號)

Name of the listed company (the “Company”): **SinoMab BioScience Limited**
上市公司（「公司」）名稱：**中國抗體製藥有限公司**

☐ I/we would like to receive future Corporate Communications* in printed form.
本人／我們欲收取未來公司通訊*的印刷版。

Name(s) of Non-registered holder(s):
非登記持有人姓名：

Signature(s): (Note 3)
簽名：(附註 3)

(Please use ENGLISH BLOCK LETTERS 請用英文正楷填寫)

Contact number:
聯絡電話號碼：

Date:
日期：

Notes: 附註：

- This letter is addressed to non-registered holder(s) of the Company (“Non-registered holder” means such person or company whose shares are held in The Central Clearing and Settlement System (CCASS) and who has notified the Company from time to time through Hong Kong Securities Clearing Company Limited that such person or company wishes to receive Corporate Communications*). 此函件乃向本公司之非登記持有人（「非登記持有人」指股份存放於中央結算及交收系統的人士或公司，已透過香港中央結算有限公司不時向本公司發出通知，表示欲收取公司通訊*）發出。
- Please complete all your details clearly. 請閣下清楚填妥所有資料。
- Any form with no box marked (✓), with no signature or otherwise incorrectly completed will be void. 如在本表格未有在方格內劃上「✓」號，或未有簽署，或在其他方面填寫不正確，則本表格將會作廢。
- For the avoidance of doubt, the Company does not accept any other instructions given on this Reply Form. 為免存疑，在本回條上的任何額外指示，公司將不予處理。

* Unless otherwise specified, Corporate Communications refer to any documents issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to the annual report, interim report, notice of meeting, circular and proxy form. 除非另有註明，公司通訊乃指公司已發出或將予發出以供其任何證券的持有人參照或採取行動的任何文件，其中包括但不限於年報、中期報告、會議通告、通函及代表委任表格。

PERSONAL INFORMATION COLLECTION STATEMENT 收集個人資料聲明

- “Personal Data” in this statement has the same meaning as “personal data” in the Personal Data (Privacy) Ordinance, Chapter 486 of the Laws of Hong Kong (“PDPO”). 本聲明中所指的「個人資料」與香港法例第 486 章《個人資料（私隱）條例》（「《私隱條例》」）中「個人資料」的涵義相同。
- Your Personal Data provided in this Reply Form will be used in connection with the Company’s electronic dissemination of Corporate Communications*. Your supply of Personal Data to the Company is on a voluntary basis. In case of a failure to provide sufficient information, the Company may not be able to process your instructions and/or requests as stated in this Reply Form. 閣下於本回條所提供的個人資料將用於有關公司以電子方式發布公司通訊*的事宜上。閣下是自願向本公司提供個人資料，若閣下未能提供足夠資料，本公司可能無法處理閣下在本回條上所述的指示及/或要求。
- Your Personal Data may be disclosed or transferred by the Company to its subsidiaries, the Share Registrar, and/or other companies or bodies for any of the stated purposes, or when it is required to do so by law and will be retained for such period as may be necessary for our verification and record purposes. 公司可就任何所說明的用途或在法例規定的情況下，將閣下的個人資料披露或轉移給公司的附屬公司、股份過戶處、及/或其他公司或團體，並將在適當期間保留該等個人資料作核實及紀錄用途。
- You have the right to request access to and/or correction of your Personal Data in accordance with the provisions of the PDPO. Any such request for access to and/or correction of your Personal Data should be in writing, by mail to the Hong Kong Privacy Officer of the Share Registrar at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong or by email at PrivacyOfficer@computershare.com.hk. 閣下有權根據《私隱條例》的條文查閱及/或修改閣下的個人資料。任何該等查閱及/或修改個人資料的要求均須以書面方式郵寄至股份過戶處（地址為香港灣仔皇后大道東 183 號合和中心 17M 樓）向香港隱私主任提出，或發送電郵至 PrivacyOfficer@computershare.com.hk。

Mailing Label 郵寄標籤

Computershare Hong Kong Investor Services Limited
香港中央證券登記有限公司
Freepost No. 簡便回郵號碼: 37
Hong Kong 香港

Please cut the mailing label and stick it on an envelope to return this form to us.
No postage is necessary if posted in Hong Kong.

當閣下寄回此回條時，請將郵寄標籤剪貼於信封上。
如在本港投寄，閣下無需支付郵費或貼上郵票。